Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021.
Link to Article:
https://www.imv-inc.com/news-events/press-releases/detail/695/imv-announces-final-topline-results-of-the-decide1-clinical
IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies for difficult-to-treat cancers, today announced the topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.
The details of these translational assessments have been submitted for presentation at upcoming scientific gatherings.
The DeCidE1 Research
The “DeCidE1” research compared the safety and efficacy of maveropepimut-S (MVP-S, also known as DPX-Survivac) with intermittent low dose cyclophosphamide in a multicenter, randomized, open-label setting (CPA). 22 patients with recurrent, advanced platinum-sensitive, and resistant ovarian cancer were enrolled in this Phase 2 experiment. Subjects received two subcutaneous MVP-S injections three weeks apart and every eight weeks thereafter, as well as intermittent low-dose CPA one week on, one week off until the end of treatment. Biopsies of the tumor were taken both before and after treatment.
The overall response rate, illness control rate, and safety were the study’s primary objectives. Cell-mediated immunity, immune cell infiltration in paired biopsy samples, duration of response, time to progression, overall survival, and biomarker studies were all secondary goals. Here’s where you can learn more about the DeCidE1 study.